Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, is reporting additional findings from its human clinical study HYPER-H21-4; the study is designed to demonstrate a potentially novel mechanism of action of LEXX’s patented DehydraTECH-processed cannabidiol (“CBD”) capsule formulation in the treatment of blood pressure (“BP”). According to the announcement, Lexaria believes that those findings, which were published in the peer-reviewed “Biomedicine and Pharmacotherapy” journal, could support DehydraTECH-CBD qualification within existing Food and Drug Administration (“FDA”) guidelines. Previous results of the study indicated that primary efficacy and safety objectives were successfully achieved, including hypertensive patients seeing resting blood pressure significantly reduced and sustained over the full five weeks of dosing; results also showed that no serious adverse events have been reported during the study.
To view the full press release, visit https://ibn.fm/En5RM
About Lexaria Bioscience Corp.
Lexaria Bioscience’s patented drug-delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bioabsorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information about the company, please visit www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
